Dramatic results seen in phase III front-line multiple myeloma trials of bortezomib-based therapy

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2008年 / 22卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [1] Bortezomib and lenalidomide as front-line therapy for multiple myeloma
    Zou, Yandun
    Lin, Mingzhen
    Sheng, Zhixin
    Niu, Shaona
    LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 2024 - 2031
  • [2] Bortezomib in the front-line treatment of multiple myeloma
    Richardson, Paul G.
    Mitsiades, Constantine
    Schlossman, Robert
    Ghobrial, Irene
    Hideshima, Teru
    Munshi, Nikhil
    Anderson, Kenneth C.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1053 - 1072
  • [3] Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease
    Agostina Siniscalchi
    Teresa Dentamaro
    Alessio Perrotti
    Paola Tatangelo
    Paolo de Fabritiis
    Tommaso Caravita
    Annals of Hematology, 2010, 89 : 821 - 822
  • [4] Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease
    Siniscalchi, Agostina
    Dentamaro, Teresa
    Perrotti, Alessio
    Tatangelo, Paola
    de Fabritiis, Paolo
    Caravita, Tommaso
    ANNALS OF HEMATOLOGY, 2010, 89 (08) : 821 - 822
  • [5] Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma
    Kortuem, Martin
    Einsele, Hermann
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (10) : 1661 - 1663
  • [6] Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study
    Kaufman, Jonathan L.
    Shah, Jatin J.
    Laubach, Jacob P.
    Mitchell, Alaina R.
    Sharp, Cathy
    Lewis, Colleen
    Harvey, R. Donald
    Gleason, Charise
    Casbourne, Daniela
    Nooka, Ajay K.
    Heffner, Leonard T.
    Richardson, Paul G.
    Orlowski, Robert Z.
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [7] BORTEZOMIB-BASED THERAPY IN FRAIL MULTIPLE MYELOMA PATIENTS
    Antonioli, E.
    Staderini, M.
    Nozzoli, C.
    Bacchiarri, F.
    Barone, F.
    Grieco, P.
    Coltro, G.
    Guarrera, A.
    Messeri, M.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 132 - 132
  • [8] Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma
    Jakubowiak, A. J.
    Hofmeister, C.
    Campagnaro, E.
    Kendall, T.
    Zimmerman, T.
    Schlossman, R.
    Reece, D.
    Lonial, S.
    Hari, M.
    Hector-Word, Z.
    Griffith, K.
    Tendler, C.
    Esseltine, D. L.
    Bock, T.
    Kaminski, M.
    Dollard, A.
    Kelley, S.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S45 - S46
  • [9] The clinical impact of frailty in transplant ineligible patients with multiple myeloma treated with bortezomib-based chemotherapy as front line therapy
    Lee, Ho Sup
    Kim, Da Jung
    Lee, Ji Hyun
    Lee, Je-Jung
    Jung, Sung-Hoon
    Jo, Jae-Cheol
    Lee, Yoo Jin
    Shin, Ho-Jin
    Lee, Won
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E11 - E12
  • [10] Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma
    Chan, Kah-Lok
    Filshie, Robin
    Nandurkar, Harshal
    Quach, Hang
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2185 - 2186
12345